This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...
The primary endpoint of the trial is disease-free ... The decision is another endorsement of the potential of V940 – also known as mRNA-4157 – which is a personalised vaccine targeting 34 ...